EGFR and glioblastoma: While EGFR overexpression did not correlate significantly with GC1118 responsiveness, the EGFRvIII variant was only detected in the sensitive group (Figure 1D), indicating the potential of GC1118 in targeting the majority of GBM tumors with EGFR alterations.